Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05004259 · ClinicalTrials.gov registry record · Phase 1
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT05004259 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT05004259, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
A single-arm study utilizing a 6 x 4 expansion design using daratumumab SC treatment for patients with refractory Autoimmune Hemolytic Anemia.
Interventions
- DRUG Daratumumab / Hyaluronidase Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2024-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05004259
The ClinicalTrials.gov registry entry for NCT05004259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daratumumab / Hyaluronidase Injection is the first listed.
NCT05004259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05004259 about?
NCT05004259 is a clinical study titled "The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia". A single-arm study utilizing a 6 x 4 expansion design using daratumumab SC treatment for patients with refractory Autoimmune Hemolytic Anemia.
What is the current status of trial NCT05004259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-03-21. Estimated completion is 2024-09-21.
What interventions are being tested in trial NCT05004259?
The interventions under investigation include: Daratumumab / Hyaluronidase Injection (DRUG).
Who is sponsoring clinical trial NCT05004259?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.